Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress

March 2, 2023

https://www.globenewswire.com/news-release/2023/03/02/2619862/0/en/Hepion-Pharmaceuticals-to-Deliver-Updates-on-Ongoing-Phase-2-NASH-Clinical-Program-with-Rencofilstat-at-6th-Global-NASH-Congress.html

EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announces that its Chief Medical Officer, Todd Hobbs, MD, will be presenting “Rencofilstat (CRV431): Update on NASH Clinical Program,” on Friday, March 3rd at the 6th Global NASH Congress held in London, England.

Read more at globenewswire.com

Related news for (HEPA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.